# Deepinder Goyal Launches Temple Wearable Amid Medical Skepticism

Zomato co-founder faces intense criticism over claims regarding his new health monitoring device.

- **Source:** [Sci-Tech News | Latest Technological Developments | The Hindu](https://www.thehindu.com/sci-tech/)
- **Published:** 2026-11-10
- **Topic:** [health](https://brifing.si/c/health)
- **Original article:** <https://www.thehindu.com/sci-tech/health/does-the-temple-wearable-reveal-useful-information-about-brain-health/article71678659.ece>
- **On Brifing:** https://brifing.si/s/c517a7b6-3677-4989-9a0b-4b8afeaa312a

## New Wearable Device Launch

Deepinder Goyal, the billionaire co-founder of Zomato and Blinkit, has officially announced the commercial availability of Temple. This new wearable device is marketed as a potential successor to current personal technology. Goyal positions the product as a revolutionary tool for monitoring human health, aiming to become humanity's last personal device.

## Founder Background and Expertise

Goyal holds a degree in Computer Science and Mathematics from the Indian Institute of Technology Delhi. Despite his success in the technology and delivery sectors, he lacks formal academic training in medical sciences or biological research. This discrepancy between his professional background and the device's health claims has fueled public debate.

## Medical Community Reactions

The announcement has triggered immediate pushback from the medical community. Physician and social media influencer Cyriac Abby Philips, known as LiverDoc, has publicly criticized the product. Philips explicitly labeled the Temple device as a scam, highlighting the lack of clinical validation or peer-reviewed evidence supporting the device's health monitoring capabilities.

## Technological Claims vs Reality

While the device is promoted as a breakthrough for brain health and personal monitoring, specific technical mechanisms remain undisclosed. The marketing narrative emphasizes a transformative impact on individual wellness. However, the absence of transparent data regarding how the wearable tracks biological signals leaves experts questioning its actual diagnostic or health utility.

## Regulatory and Ethical Concerns

The launch raises significant questions regarding the regulation of health-tech products developed by non-medical entrepreneurs. Without clear clinical trials or regulatory approval, the device enters a crowded market of consumer wearables. Critics argue that marketing such products as medical tools without rigorous scientific backing poses risks to consumer health and safety.

## Market Context and Positioning

Goyal’s entry into the health-tech space reflects a broader trend of tech billionaires diversifying into biotechnology and wellness. By leveraging his reputation from Zomato and Blinkit, he seeks to capture the growing demand for personal health data. Yet, the transition from food delivery logistics to medical diagnostics remains highly controversial.

## Public and Digital Discourse

The debate surrounding Temple has played out largely on social media platforms, where influencers and medical professionals engage in direct confrontation. This digital discourse highlights the tension between tech-driven innovation and established medical standards. Public perception remains divided between those trusting Goyal's track record and those demanding strict scientific evidence.

## Future Outlook for Temple

The long-term viability of the Temple device depends on whether Goyal can provide verifiable clinical data to satisfy skeptical medical experts. Without such evidence, the product risks being dismissed as a marketing exercise rather than a legitimate health tool. Future developments will depend on regulatory scrutiny and the company's transparency regarding data.

## Sources covering this story

- https://www.thehindu.com/sci-tech/health/does-the-temple-wearable-reveal-useful-information-about-brain-health/article71678659.ece — 

---

_Summary written by Brifing from the original reporting. Copyright in the original article belongs to its publisher; read the full piece at the link above._
